AzTrials
AzTrials

Healthy ControlGARBOZNCT00840528

Genetic Susceptibility TO Ozone-induced Airway Inflammation in Humans

A study testing ozone in people with Healthy Control, run by University of North Carolina, Chapel Hill at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The principal purpose of this study is to identify hyper-responsive, responsive and non-responsive groups of healthy human subjects based on their airway neutrophilic response to ozone exposure, and to perform micro-array analyses on DNA collected from recovered airway cells to explore possible differences in gene… Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Control
What is being tested?
ozone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
84 participants
Where
1 siteUnited States
Study dates
Feb 2002to 20 Jun 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Subjects will have an FEV1/FVC equal to or greater than 75%, as well as FVC and FEV1 greater than or equal to 80% of predicted normal for height and age.
  • Skin testing will be performed; subjects with active allergies will not be studied while they are symptomatic.
  • Subjects must be in good general health with no history of acute or chronic cardiovascular disease, chronic respiratory disease, and acute respiratory illness within 4 weeks, and without contraindications for performing sustained light to moderate exercise.
  • Subjects must demonstrate the ability to produce an acceptable induced sputum sample during the training session. If the sample is unsatisfactory, the subject's participation will end at this point.
  • Antidepressants and other medications may be permitted if in the opinion of the investigator the medication will not interfere with the study procedures or compromise safety; and if the dosage has been stable for 3 months.
  • Subjects must smoke less than 10 cigarettes (one half pack) a month for at least 3 years. Individuals who have smoked greater than 10 pack years lifetime will be excluded.
  • Subjects must be willing to refrain from strenuous physical activity for 24 hours before and after exposure.

Who cannot join

  • asthmatic or active allergic rhinitis
  • Non English speaking volunteers will be excluded as no one on the study staff is fluent in other languages likely to be encountered.
  • use anti-inflammatory medications or medications for asthma

Trial locations and contacts

1 site in 1 country.

United States1 site
  • US EPA Human Studies Facility

    Chapel Hill, North Carolina, 27514

Other trials in United States

About this study

Official title: Genetic Susceptibility TO Ozone-induced Bronchial Airway Inflammatory Responses In Humans

The principal purpose of this study is to identify hyper-responsive, responsive and non-responsive groups of healthy human subjects based on their airway neutrophilic response to ozone exposure, and to perform micro-array analyses on DNA collected from recovered airway cells to explore possible differences in gene expression profiles between the three groups

Read the detailed description

Sputum assessment day: Subjects meeting the required health status following the medical screening will be provided with a verbal and written description of all experimental procedures and possible risks involved in their participation. All subjects will be required to provide written informed consent to participate in the study. The ability of subjects to produce adequate induced sputum samples will also be determined. Therefore the subjects will be asked to produce sputum following inhalation of hypertonic saline (3, 4 and 5%). Subjects should be able to produce at least 50 mg of sputum (selected plug) per sample. Each sputum sample must contain a total cell count of at least 100,000 cells, a differential cell count containing less than 40% squamous epithelial cells, and cell viability of at least 50%, thus minimizing variability in cell recovery and squamous cell contamination. Subjects who are effective sputum producers will then be scheduled for a training session. Subjects may still be excluded from the study if unable to perform adequate pulmonary function tests.

Training session: Training session will occur no less than 2 days prior to exposure

  • Lung function tests, including spirometry and plethysmography (body box measurements).
  • Introduction to the ozone exposure chamber.
  • Instruction on how to use the treadmill, including a minute ventilation measurement to reach the level of exercise required for the study.
  • Nitric oxide measurement - this measures the amount of nitric oxide (NO) present in expired air. An increased concentration of NO in exhaled air may be found in normal persons with acute inflammation during upper respiratory tract infections and in association with symptoms in patients with allergic rhinitis. Thus, measurement of the concentration of NO in expired air may be useful as an indirect assessment of airway inflammation. Lung production of NO will be measured by collection of a sample of exhaled gas. Nasal production of NO will be measured directly by connecting a NO analyzer sampling line to one nostril with the other nostril open to ambient air. During the nasal measurement the subject will exhale through a cardboard, disposable tube with a resistance in order to close the palate and prevent contamination of the nasal sample with. The entire procedure should be completed in less than 15 minutes.

Exposure and testing protocol: Upon arrival at the laboratory, subjects' clinical health status will be ascertained by medical personnel, including base line heart rate, blood pressure, evaluation of respiratory symptoms (breath sounds) and general health. All female subjects will be required to provide a menstrual cycle history and a urine sample will be required for pregnancy testing. Each pregnancy test will be considered valid for 7 days. Testing will be postponed if a subject exceeds previously established limits.

The 0.4 ppm ozone exposure will be conducted in an ozone exposure chamber. Each subject will be exposed to ozone for 2 hours. During the exposure, subjects will perform four 15 minute bouts of moderate exercise (minute ventilation or VE = 30 40 L/min) on a treadmill, each separated by 15 minutes of seated rest. Before and after exposure, lung function and breath sounds will be assessed for any signs of bronchial constriction. Venipuncture (as noted above) will occur prior to exposure. Measurements of cardiorespiratory performance will be obtained during each exercise period.

Approximately 4-6 hours following ozone exposure, venipuncture will occur. Subjects will perform the sputum induction procedures described above with nebulized inhaled hypertonic saline (3, 4 and 5%). The subject will remain under medical supervision until pulmonary function (spirometry) returns to within 5% of pre-exposure baseline values before leaving the laboratory. Approximately 24 hours after the ozone exposure, subjects will return to the laboratory for lung function testing and sputum induction, in addition to a venous blood sample.

At each time point (pre and post exposure, and 24 hours post exposure), blood will be drawn from the vein in forearm into clinical lab tubes. During one of these blood draws the additional 5ml will be drawn for genotyping. Plasma will be separated from 4 ml and frozen at 70 degrees C for future analysis of mediators of interest, such as cytokines, as well as other systemic effects of ozone. The remaining blood will be assessed by whole blood assays for markers of inflammatory and immune activation (CD11b, CD14, CD64, CD16, HLA-DR, CD45, CD3, CD80, CD86) and function (phagocytosis and oxidative burst) by two colour flow cytometry. RNA will be extracted from sputum inflammatory cells for microarray analysis,.

During the course of participation all subjects will be required to abstain from; ingestion of Vitamins C and E, aspirin or any other anti-inflammatory medication, exposure to cigarette smoke or other irritants. In addition, subjects will be asked to have nothing by mouth for 2 hours before sputum induction. They will be asked to arrive in the research lab NPO x 2 hours on training day and post exposure day, and will have lunch on exposure day at a time that will allow for the 2 hour NPO requirement.

Conditions
Healthy Control
Being tested
ozone
Keywords
ozone

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ozoneOther

    Also called O3

    0.4 ppm ozone for 2 hours

Study groups in NCT00840528
Study groupRoleWhat they receive
Ozone exposureExperimentalExposure to ozone at 0.4ppm
Receives: Other: ozone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Airway neutrophilic response to ozone exposure

    Measured: 6-24 hours post challenge

Secondary outcomes (1)
  1. expression of specific genes of interest in a subset of ozone-responsive and ozone-non-responsive subjects

    Measured: pre/ post exposure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Feb 2009 (estimated)
  2. Study startFeb 2002
  3. Primary completion20 Jun 2017
  4. Study completion20 Jun 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
84 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00840528
Sponsor's protocol ID
02-1416
Other IDs
NIH/NIEHS 1RC1ES018417
Acronym
GARBOZ
Status last verified
Sep 2017
First submitted
6 Feb 2009
Last updated
25 Sep 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing ozone in people with Healthy Control, run by University of North Carolina, Chapel Hill at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Airway neutrophilic response to ozone exposure (time frame: 6-24 hours post challenge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in